1 active not recruiting, 1 completed, 1 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
Follow Severe Hemophilia A: new trials by email Literature Review of Severe Hemophilia A trials Research Report on Severe Hemophilia A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A GS1191-0445 injection - Severe Hemophilia A | Phase 1 / Phase 2 | Active not recruiting | Gritgen Therapeutics Co., Ltd. | 7 | 2023-07-10 | 2026-05-06 |
| A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection FRSW117 - Severe Hemophilia A | Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 15 | 2022-04-14 | 2023-05-15 |
| Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A OCTA101 - Severe Hemophilia A | Phase 1 / Phase 2 | Terminated | Octapharma | 36 | 2019-07-03 | 2026-10-15 |
Hemophilia A (3) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Hemic and Lymphatic Diseases (3) · Blood Coagulation Disorders (2) · Blood Coagulation Disorders, Inherited (2) · Coagulation Protein Disorders (2) · Genetic Diseases, Inborn (2) · Hematologic Diseases (2) · Hemorrhagic Disorders (2)
Injections (1)
Gritgen Therapeutics Co., Ltd. (1) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (1) · Octapharma (1)
China (2) · Bulgaria (1)
Renchi Yang, PhD (1)